Skip to main content
SpringerLink
Log in

Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association with weight gain and changes in blood glucose and lipid parameters. We find a relative paucity of studies in this area; while some data highlight significant, collective changes in metabolic parameters, the majority suggests an apparent low vulnerability to these side effects. We conclude that the risk and clinical implications of unfavorable metabolic changes in the elderly being treated with AAP medications remain largely undetermined, and we caution against drawing firm conclusions based on the available data. The conflicting evidence leaves us recommending that metabolic monitoring be implemented, with regular follow-up as advocated in other populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shah SM, Carey IM, Harris T, Dewilde S, Cook DG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26(4):423–34.

    CAS  PubMed  Google Scholar 

  2. Monshat K, Carty B, Olver J, Castle D, Bosanac P. Trends in antipsychotic prescribing practices in an urban community mental health clinic. Australas Psychiatry. 2010;18(3):238–41.

    PubMed  Google Scholar 

  3. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9–18.

    PubMed  Google Scholar 

  4. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68(2):e04.

    PubMed  Google Scholar 

  5. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

    CAS  PubMed  Google Scholar 

  6. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68.

    CAS  PubMed  Google Scholar 

  8. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology. 2000;148(1):3–15.

    CAS  PubMed  Google Scholar 

  9. Purdon SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci. 2000;25(2):108–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.

    CAS  PubMed  Google Scholar 

  11. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39(10):1591–602.

    CAS  PubMed  Google Scholar 

  12. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25.

    PubMed  Google Scholar 

  13. Taylor DM, McAskill R. Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand. 2000;101(6):416–32.

    CAS  PubMed  Google Scholar 

  14. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.

    CAS  PubMed  Google Scholar 

  15. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.

    CAS  PubMed  Google Scholar 

  16. Association CP. Compendium of pharmaceuticals and specialties (CPS). Ottawa: Canadian Pharmacists Association; 2012.

    Google Scholar 

  17. Physicians’ Desk Reference. 66th ed. Montvale: Thompson PDR; 2012.

  18. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm. 2005;11(1):17–24.

    PubMed  Google Scholar 

  19. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res. 2001;35(3):187–91.

    CAS  PubMed  Google Scholar 

  20. Lee PE, Gill SS, Rochon P. Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. Neuropsychiatr Dis Treat. 2006;2(4):521–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.

    CAS  PubMed  Google Scholar 

  22. Administration FaD. Antipsychotics: conventional and atypical. 2005 [cited 2013 August 3]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm.

  23. US Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. US FDA, 2008.

  24. Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, et al. Trends in antipsychotic use in dementia 1999–2007. Arch Gen Psychiatry. 2011;68(2):190–7.

    PubMed  Google Scholar 

  25. Schulze J, van den Bussche H, Glaeske G, Kaduszkiewicz H, Wiese B, Hoffmann F. Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur Neuropsychopharmacol. 2013;23(9):1034–42.

    Google Scholar 

  26. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.

    PubMed  Google Scholar 

  27. British Columbia Ministry of Health. A review of the use of antipsychotic drugs in British Columbia residential care facilities. BC MoH; 2011. http://www.health.gov.bc.ca/library/publications/year/2011/use-of-antipsychotic-drugs.pdf

  28. Lipkovich I, Ahl J, Nichols R, Hardy T, Poole Hoffmann V. Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances. J Geriatr Psychiatry Neurol. 2007;20(2):107–14.

    PubMed  Google Scholar 

  29. Micca JL, Hoffmann VP, Lipkovich I, Ahl J, Baker RW, Hardy TA. Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials. Am J Geriatr Psychiatry. 2006;14(1):62–70.

    PubMed  Google Scholar 

  30. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study. Am J Psychiatry. 2009;166(5):583–90.

    PubMed Central  PubMed  Google Scholar 

  31. Rondanelli M, Sarra S, Antoniello N, Mansi V, Govoni S, Falvo F, et al. No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer’s disease. Minerva Med. 2006;97(2):147–51.

    CAS  PubMed  Google Scholar 

  32. Albert SG, Grossberg GT, Thaipisuttikul PJ, Scouby J, Green E. Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study. J Am Med Dir Assoc. 2009;10(2):115–9.

    PubMed  Google Scholar 

  33. Gurevitz SL, Costakis T, Leiter J. Do atypical antipsychotics cause weight gain in nursing home dementia residents? Consult Pharm. 2004;19(9):809–12.

    PubMed  Google Scholar 

  34. Mathys M, Blaszczyk A, Busti A. Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. Consult Pharm. 2009;24(3):201–9.

    PubMed  Google Scholar 

  35. Goldberg RJ. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc. 2001;2(1):26–8.

    CAS  PubMed  Google Scholar 

  36. Teresa Amboage-Paz M, Antonio Díaz-Peromingo J. Effect of risperidone on serum lipids and cerebrovascular mortality among elderly dementia patients with associated behavioral disturbances. Int J Psychiatry Clin Pract. 2008;12(3):196–201.

    Google Scholar 

  37. Finkel B, Goodman C, Melamed Y, Naser M, Andreyev P, Segev Y, Bleich A. Differences in metabolic side-effects of typical and atypical antipsychotic treatment in elderly individuals with long-term schizophrenia. Hong Kong J Psychiatry. 2009;19:103–6.

    Google Scholar 

  38. Barak Y, Aizenberg D. Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drugs Aging. 2003;20(12):893–6.

    CAS  PubMed  Google Scholar 

  39. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry. 2002;63(2):117–9.

    PubMed  Google Scholar 

  40. Martinez Romero G, Peris Marti JF, Gomar Fayos J, Navarro Gosalbez M, Quintana Vargas I, Muelas Tirado J. [Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2010;34(3):139–47.

  41. Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–31.

    PubMed  Google Scholar 

  42. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19(2):115–26.

    PubMed  Google Scholar 

  43. Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, et al. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer’s dementia. Int J Geriatr Psychiatry. 2005;20(11):1020–7.

    PubMed  Google Scholar 

  44. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76.

    CAS  PubMed  Google Scholar 

  45. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer’s dementia. Int J Geriatr Psychiatry. 2001;16(Suppl 1):S62–70.

    PubMed  Google Scholar 

  46. Deberdt WG, Dysken MW, Rappaport SA, Feldman PD, Young CA, Hay DP, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13(8):722–30.

    PubMed  Google Scholar 

  47. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007;4(1):81–93.

    CAS  PubMed  Google Scholar 

  48. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134–43.

    CAS  PubMed  Google Scholar 

  49. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53(5):946–55.

    PubMed  Google Scholar 

  50. Gareri P, Cotroneo A, Lacava R, Seminara G, Marigliano N, Loiacono A, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl. 2004;9:207–15.

    CAS  PubMed  Google Scholar 

  51. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6):662–71.

    CAS  PubMed  Google Scholar 

  52. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52(5):438–45.

    CAS  PubMed  Google Scholar 

  53. Madhusoodanan S, Brenner R, Suresh P, Concepcion NM, Florita CD, Menon G, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry. 2000;12(1):11–8.

    CAS  PubMed  Google Scholar 

  54. Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1199–202.

    CAS  PubMed  Google Scholar 

  55. Mazeh D, Paleacu D, Barak Y. Quetiapine for elderly non-responsive schizophrenia patients. Psychiatry Res. 2008;157(1–3):265–7.

    CAS  PubMed  Google Scholar 

  56. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol. 2000;13(1):28–32.

    CAS  PubMed  Google Scholar 

  57. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol. 2002;22(2):115–20.

    CAS  PubMed  Google Scholar 

  58. Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry. 2004;19(9):898–905.

    PubMed  Google Scholar 

  59. Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000;15(6):506–14.

    CAS  PubMed  Google Scholar 

  60. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11(6):638–47.

    PubMed  Google Scholar 

  61. Dubovsky SL, Frobose C, Phiri P, de Greef R, Panagides J. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry. 2012;27(5):472–82.

    PubMed  Google Scholar 

  62. Hwang JP, Yang CH, Lee TW, Tsai SJ. The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol. 2003;23(2):113–8.

    CAS  PubMed  Google Scholar 

  63. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999;60(5):292–8.

    CAS  PubMed  Google Scholar 

  64. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22(9):1068–84.

    CAS  PubMed  Google Scholar 

  65. Yang CH, Tsai SJ, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol. 2005;19(6):661–6.

    CAS  PubMed  Google Scholar 

  66. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767–76.

    PubMed  Google Scholar 

  67. Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics—risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11(3):113–8.

    CAS  PubMed  Google Scholar 

  68. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.

    CAS  PubMed  Google Scholar 

  69. Jalbert JJ, Daiello LA, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. Am J Geriatr Pharmacother. 2011;9(3):153–63.

    CAS  PubMed  Google Scholar 

  70. Klebovich A, Hanko B, Orban K, Zelko R. Antipsychotic treatment and the prevalence of diabetes among elderly patients in psychiatric rehabilitation. Arch Gerontol Geriatr. 2009;48(1):19–21.

    CAS  PubMed  Google Scholar 

  71. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159(4):561–6.

    PubMed  Google Scholar 

  72. Lipscombe LL, Levesque LE, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am J Geriatr Psychiatry. 2011;19(12):1026–33.

    PubMed  Google Scholar 

  73. Erickson SC, Le L, Zakharyan A, Stockl KM, Harada AS, Borson S, et al. New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc. 2012;60(3):474–9.

    PubMed  Google Scholar 

  74. Lipscombe LL, Levesque L, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med. 2009;169(14):1282–9.

    CAS  PubMed  Google Scholar 

  75. Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, et al. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc. 2004;5(1):38–46.

    PubMed  Google Scholar 

  76. Etminan M, Streiner DL, Rochon PA. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy. 2003;23(11):1411–5.

    CAS  PubMed  Google Scholar 

  77. Hammerman A, Dreiher J, Klang SH, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008;42(9):1316–22.

    PubMed  Google Scholar 

  78. Kisely S, Cox M, Campbell LA, Cooke C, Gardner D. An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Can J Psychiatry. 2009;54(4):269–74.

    PubMed  Google Scholar 

  79. Prevention CfDCa. Percentage of civilian, non institutionalized population with diagnosed diabetes, by age, United States, 1980–2007; 2009.

  80. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996;39(11):1392–7.

    CAS  PubMed  Google Scholar 

  81. Vidarsdottir S, Vlug P, Roelfsema F, Frolich M, Pijl H. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry. 2010;71(9):1205–11.

    CAS  PubMed  Google Scholar 

  82. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol. 2008;11(5):679–84.

    CAS  PubMed  Google Scholar 

  83. Cohen HJ. In search of the underlying mechanisms of frailty. J Gerontol Ser A Biol Sci Med Sci. 2000;55(12):M706–8.

    CAS  Google Scholar 

  84. Sandman PO, Adolfsson R, Nygren C, Hallmans G, Winblad B. Nutritional status and dietary intake in institutionalized patients with Alzheimer’s disease and multiinfarct dementia. J Am Geriatr Soc. 1987;35(1):31–8.

    CAS  PubMed  Google Scholar 

  85. White H, Pieper C, Schmader K. The association of weight change in Alzheimer’s disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46(10):1223–7.

    CAS  PubMed  Google Scholar 

  86. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

    CAS  PubMed  Google Scholar 

  87. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–35.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull. 1993;19(4):817–30.

    CAS  PubMed  Google Scholar 

  89. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547–62.

    CAS  PubMed  Google Scholar 

  90. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36(4):239–45.

    CAS  PubMed  Google Scholar 

  91. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.

    CAS  PubMed  Google Scholar 

  92. Balf G. Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics. Am J Psychiatry. 2008;165(9):1206–7 author reply 7.

    PubMed  Google Scholar 

  93. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(Suppl 1):20–7.

    CAS  PubMed  Google Scholar 

  94. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–49.

    PubMed  Google Scholar 

  95. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125–47.

    CAS  PubMed  Google Scholar 

  96. Copeland LA, Parchman ML, Zeber JE, Lawrence VA, Downs JR, Miller AL. Prediabetes assessment and follow-up in older veterans with schizophrenia. Am J Geriatr Psychiatry. 2010;18(10):887–96.

    PubMed  Google Scholar 

  97. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.

    PubMed  Google Scholar 

  98. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23(4):583–609.

    CAS  PubMed  Google Scholar 

  99. Akbostanci MC, Atbasoglu EC, Balaban H. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg. 1999;99(3):176–81.

    CAS  PubMed  Google Scholar 

  100. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(Suppl 9):21–4.

    CAS  PubMed  Google Scholar 

  101. Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol. 2004;57(5):540–4.

    CAS  PubMed Central  PubMed  Google Scholar 

  102. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70(3):397–405.

    CAS  PubMed  Google Scholar 

  103. Irizarry MC, Ghaemi SN, Lee-Cherry ER, Gomez-Isla T, Binetti G, Hyman BT, et al. Risperidone treatment of behavioral disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci. 1999;11(3):336–42.

    CAS  PubMed  Google Scholar 

  104. Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):917–20.

    CAS  PubMed  Google Scholar 

  105. Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst. 1969;30(5):341–4.

    CAS  PubMed  Google Scholar 

  106. Marinow A. Diabetes in chronic schizophrenia. Dis Nerv Syst. 1971;32(11):777–8.

    CAS  PubMed  Google Scholar 

  107. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66(4):504–14.

    CAS  PubMed  Google Scholar 

  108. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(Suppl 23):30–8.

    CAS  PubMed  Google Scholar 

  109. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903–12.

    CAS  PubMed  Google Scholar 

  110. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl. 2004;47:S76–9.

    PubMed  Google Scholar 

  111. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74(16):1999–2008.

    CAS  PubMed  Google Scholar 

  112. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51(6):382–6.

    PubMed  Google Scholar 

  113. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267–72.

    Google Scholar 

  114. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32:S1–S201.

    Google Scholar 

  115. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64–74.

    PubMed  Google Scholar 

  116. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer’s disease. J Alzheimers Dis. 2009;16(4):693–704.

    PubMed Central  PubMed  Google Scholar 

  117. Luchsinger JA. Adiposity, hyperinsulinemia, diabetes and Alzheimer’s disease: an epidemiological perspective. Eur J Pharmacol. 2008;585(1):119–29.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology. 2013;226(1):1–12.

    CAS  PubMed  Google Scholar 

  119. Vidarsdottir S, de Leeuw van Weenen JE, Frolich M, Roelfsema F, Romijn JA, Pijl H. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab. 2010;95(1):118–25.

    CAS  PubMed  Google Scholar 

  120. Assie MB, Carilla-Durand E, Bardin L, Maraval M, Aliaga M, Malfetes N, et al. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol. 2008;592(1–3):160–6.

    CAS  PubMed  Google Scholar 

  121. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32(2):289–97.

    CAS  PubMed  Google Scholar 

  122. Boyda HN, Tse L, Procyshyn RM, Wong D, Wu TK, Pang CC, et al. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):945–54.

    CAS  PubMed  Google Scholar 

  123. Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, Nobrega J, et al. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res. 2009;108(1–3):127–33.

    PubMed  Google Scholar 

  124. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, et al. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 2008;28(5):494–9.

    CAS  PubMed  Google Scholar 

  125. Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011;131(1–3):90–5.

    PubMed  Google Scholar 

  126. Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, et al. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model. Schizophr Res. 2013;146(1–3):162–9.

    PubMed  Google Scholar 

  127. Smith GC, Vickers MH, Shepherd PR. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem. 2011;117(4):241–9.

    CAS  PubMed  Google Scholar 

  128. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64(5):598–604.

    CAS  PubMed  Google Scholar 

  129. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res. 2003;60(1):99–100.

    PubMed  Google Scholar 

  130. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1–17.

    PubMed  Google Scholar 

  131. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.

    CAS  PubMed  Google Scholar 

  132. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51(8):492–501.

    PubMed  Google Scholar 

  133. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650–64.

    PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of Interest and Funding Statement

Melanie Guenette and Araba Chintoh have no conflicts of interest that are relevant to this manuscript. Margaret Hahn has received a one-time speaker’s fee from Novartis. Gary Remington has received research support from Novartis, Neurocrine Biosciences, and Medicure. He has also received consultant’s fees from Synchroneuron, and speaker’s fees from Novartis. No funding was used to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Institute of Medical Science, University of Toronto, 1 King’s College Circle, Toronto, M5S1A8, Canada

    Melanie Dawn Guenette & Gary Remington

  2. Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada

    Melanie Dawn Guenette, Araba Chintoh, Gary Remington & Margaret Hahn

  3. Department of Psychiatry, University of Toronto, 250 College St, Toronto, ON, M5T 1R8, Canada

    Gary Remington & Margaret Hahn

Authors
  1. Melanie Dawn Guenette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Araba Chintoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Remington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margaret Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret Hahn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guenette, M.D., Chintoh, A., Remington, G. et al. Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly. Drugs Aging 31, 159–184 (2014). https://doi.org/10.1007/s40266-014-0152-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-014-0152-x

Keywords

Search

Navigation